Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
Curr Opin Crit Care. 2020 Dec;26(6):590-595. doi: 10.1097/MCC.0000000000000763.
The aim of this study was to describe our knowledge about the use of epinephrine in cardiac arrest and discuss the unknowns and current controversies.
A recent large, well conducted, double-blind, randomized placebo-controlled trial of over 8000 patients with out-of-hospital cardiac arrest (PARAMEDIC-2) showed that epinephrine increased return of spontaneous circulation and survival to hospital discharge. The trial's secondary outcomes have raised concerns that epinephrine increases the number of brain damaged survivors. Systematic review and meta-analysis suggest that epinephrine has more pronounced effects for nonshockable rhythms, when given early, and probably increases the number of both good and poor survivors. There remains uncertainty about the optimal use of epinephrine in terms of patient groups, rhythms, dose and timing.
Epinephrine still has a role in the treatment of cardiac arrest; the best way to use epinephrine remains uncertain.
本研究旨在描述我们对肾上腺素在心脏骤停中的应用的认识,并讨论未知和当前存在的争议。
最近一项针对 8000 多名院外心脏骤停患者的大型、精心设计的、双盲、随机安慰剂对照试验(PARAMEDIC-2)表明,肾上腺素增加了自主循环恢复和存活至出院的几率。该试验的次要结果引起了人们的关注,即肾上腺素增加了脑损伤幸存者的数量。系统评价和荟萃分析表明,肾上腺素对非电击性节律的作用更为明显,在早期给予时效果更好,并且可能增加了数量良好和不良的幸存者。在患者群体、节律、剂量和时机方面,肾上腺素的最佳使用仍存在不确定性。
肾上腺素在心脏骤停的治疗中仍有作用;使用肾上腺素的最佳方法仍不确定。